1 / 13

Mycosis Fungoides and Sezary Syndrome

Mycosis Fungoides and Sezary Syndrome. Definitions. Mycosis fungoides: Extranodal Non-Hodgkins lymphoma of T-cell origin, with primary involvement of the skin Sezary Syndrome: Generalized erythroderma Lymphadenopathy Atypical T- cells (Sezary cells) in the peripheral blood. Epidemiology MF.

chidi
Download Presentation

Mycosis Fungoides and Sezary Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mycosis Fungoides and Sezary Syndrome

  2. Definitions • Mycosis fungoides: • Extranodal Non-Hodgkins lymphoma of T-cell origin, with primary involvement of the skin • Sezary Syndrome: • Generalized erythroderma • Lymphadenopathy • Atypical T- cells (Sezary cells) in the peripheral blood

  3. Epidemiology MF • 3 cases/ 1,000,000/ year<1000/year US • Peak age 55-60 • Male: female 2:1 TIMycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. AUWeinstock MA; Horm JW SOJAMA 1988 Jul 1;260(1):42-6.

  4. Clinical • Indolent cutaneous eruption with erythematous scaly patches or plaques, typically bathing trunk distribution • Heterogeneity in presentation

  5. Extracutaneous Disease • Progression to Extracutaneous disease correlates with extent of skin disease • Limited patch or plaque very rare • Generalized plaque 8 % • Tumorous or generalized erythroderma30-40% Hoppe RT, Kim YH,Clinical features, staging, and prognosis of mycosis fungoides and Sezary syndrome, Uptodate.com, 11/06

  6. Histology Hoppe RT, Kim YH,Clinical features, staging, and prognosis of mycosis fungoides and Sezary syndrome, Uptodate.com, 11/06

  7. Sezary Cell Hoppe RT, Kim YH,Clinical features, staging, and prognosis of mycosis fungoides and Sezary syndrome, Uptodate.com, 11/06

  8. TNMB classification system for mycosis fungoides • T1 Limited patch/plaque (< 10 percent of total skin surface) • T2 Generalized patch/plaque (>10 percent of total skin surface) • T3 Tumors • T4 Generalized erythroderma • N0 Lymph nodes clinically uninvolved • N1 Lymph nodes enlarged, histologically uninvolved (includes "reactive" and "dermatopathic" nodes) • N2 Lymph nodes clinically uninvolved but histologically involved • N3 Lymph nodes enlarged and histologically involved • M0 No visceral involvement • M1 Visceral involvement (histologically confirmed) • B0 No circulating atypical (Sezary) cells (< 5 percent of lymphocytes) • B1 Circulating atypical (Sezary) cells ( 5 percent of lymphocytes)

  9. Prognosis By Tumor Extent Mycosis fungoides and Sézary Syndrome. Semin Oncol 1999; 26:276. figure 1, page 279.

  10. Transformation to Large Cell • One study of 115 pt’s; 39 % with transfomation over 12 year follow up • Median time to transformation of 12 m

  11. Hoppe RT, Kim YH,Clinical features, staging, and prognosis of mycosis fungoides and Sezary syndrome, Uptodate.com, 11/06

More Related